The influence of clinical variables on hospital costs after orthotopic liver transplantation

Surgery

Volumn 125, Issue 2, 1999, Pages 217-222

  Whiting, James F ^a   Martin, Jill ^b   Zavala, Edward ^b   Hanto, Douglas ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DIALYSIS; FEMALE; GRAFT REJECTION; HOSPITAL COST; HUMAN; LENGTH OF STAY; LIVER TRANSPLANTATION; MALE; MULTIVARIATE ANALYSIS; MYCOSIS; PRIORITY JOURNAL; REOPERATION; RESOURCE MANAGEMENT; RETROSPECTIVE STUDY;

EID: 0032980031     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(99)70268-0     Document Type: Article

References (25)

1. 1. Finkler SA. The distinction between costs and charges. Arch Intern Med 1982;96:102-9.
2. 2. Haley RW. Measuring the costs of nosocomial infections: methods for estimating economic burden on the hospital. Am J Med 1991;91:32-8S.
3. 3. Macario A, Vitez TS, Dunn B, McDonald T. Where are the costs in perioperative care? Analysis of hospital costs and charges for inpatient surgical care. Anesthesiology 1995;83:1138-44.
4. 4. Orloff TM, Littell CL, Clune C, Klingman D, Preston B. Hospital cost accounting: who's doing what and why. Health Care Manage Rev 1990;15:73-8.
5. 5. Baptist AJ. A general approach to costing procedures in ancillary departments. Top Health Care Fin 1987:13:32-47.
6. 6. UNOS. Graft and patient survival rates. In: UNOS 1996 annual report. Washington: US Department of Health and Human Services; 1997. p 144.
7. 7. Kim WR, Therneau TM, Dickson ER, Evans RW. Preoperative predictors of resource utilization in liver transplantation. In: Cecka JM, Terasaki PI, editors. Clinical transplants 1995. Los Angeles: University of California, Los Angeles; 1995. p 315-22.
8. 8. Brown RS Jr, Ascher NL, Lake JR, Emond JC, Bacchem P, Randall HB, et al. The impact of surgical complications after liver transplantation on resource utilization. Ann Surg 1997;132:1098-103.
9. 9. Falagas ME, Arbo M, Ruthazer R, Griffith JL, Werner BG, Rohrer R, et al. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation 1997;63:1595-601.
10. 10. Travis JF. Bottoms up accounting systems: a superior method for controlling health care costs. Mod Healthcare 1977;17:50-5.
11. 11. Whiting JF, Rossi SJ, Hanto DW. Infectious complications after OKT3 induction in liver transplantation. Liver Transplant Surg 1997;3:563-70.
12. 12. UNOS. 1997 Report of center specific graft and patient survival rates. Washington: Department of Health and Human Services; 1997.
13. 13. Powe NR, Griffiths RI. The clinical-economic trial: promise, problems and challenges. Controlled Clin Trials 1995;16:377-94.
14. 14. Eisenberg JM. A guide to the economic analysis of clinical practices. JAMA 1989;262:2879-86.
15. 15. Mora NP, Gonwa TA, Goldstein RM, Husberg BS, Klintmalm GB. Risk of postoperative infection after liver transplantation: a univariate and stepwise logistic regression analysis of risk factors in 150 consecutive patients. Clin Transplantation 1992;46:443-9.
16. 16. Bein T, Forst H, Pratschke E. Apache-II-scoring in the liver transplant recipient. Intensive Care Med 1997;18:60-1.
17. 17. Shaw BW Jr, Wood RP, Gordon RD, Iwatsuki S, Gillquist WP, Starzl TE. Influence of selected patient variables and operative blood loss on six-month survival following liver transplantation. Semin Liver Dis 1985;5:385-93.
18. 18. Evans RW. A cost-outcome analysis of retransplantation: the need for accountability. Transplant Rev 1993;7:163-8.
19. 19. Whiting JF, Fecteau A, Bejarano P, Hanto DW. Use of of low-dose OKT3 as induction therapy in liver transplantation. Transplantation 1998;65:577-80.
20. 20. Martin JE, Fleck P, Schroeder TJ, Whiting JF, Hanto DW. The cost of rejection in liver allograft recipients. Transplant Proc 1998;30:1500-1
21. 21. Snydman DR, Werner BG, Dougherty NN, Griffith J, Rubin RH, Dienstag JL, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized, double-blind, placebo-controlled trial. The Boston Center for Liver Transplantation. Ann Intern Med 1993;119:984-91.
22. 22. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Miner BA, et al. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. Ann Intern Med 1994;120:375-81.
23. 23. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995;346:69-74.
24. 24. Patel R, Snydman DR, Rubin RH, Ho M, Pescovitz M, Martin M, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996;61:1279-89.
25. 1 in liver transplantation. Hepatology 1995;21:366-372.